0000899243-20-028430.txt : 20201015 0000899243-20-028430.hdr.sgml : 20201015 20201015202439 ACCESSION NUMBER: 0000899243-20-028430 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201013 FILED AS OF DATE: 20201015 DATE AS OF CHANGE: 20201015 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mahadevia Ankit CENTRAL INDEX KEY: 0001720974 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38266 FILM NUMBER: 201242549 MAIL ADDRESS: STREET 1: C/O SPERO THERAPEUTICS, INC. STREET 2: 675 MASSACHUSETTS AVE., 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Spero Therapeutics, Inc. CENTRAL INDEX KEY: 0001701108 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 675 MASSACHUSETTS AVENUE STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-242-1600 MAIL ADDRESS: STREET 1: 675 MASSACHUSETTS AVENUE STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Spero Therapeutics, LLC DATE OF NAME CHANGE: 20170316 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-10-13 0 0001701108 Spero Therapeutics, Inc. SPRO 0001720974 Mahadevia Ankit C/O SPERO THERAPEUTICS, INC. 675 MASSACHUSETTS AVENUE, 14TH FLOOR CAMBRIDGE MA 02139 1 1 0 0 CEO and President Common Stock 2020-10-13 4 M 0 14367 5.90 A 80184 D Common Stock 2020-10-13 4 S 0 14367 14.2836 D 65817 D Common Stock 2020-10-14 4 M 0 105 5.90 A 65922 D Common Stock 2020-10-14 4 S 0 105 14.25 D 65817 D Stock Option (Right to Buy) 5.90 2020-10-13 4 M 0 14367 0.00 D 2027-07-05 Common Stock 14367 504441 D Stock Option (Right to Buy) 5.90 2020-10-14 4 M 0 105 0.00 D 2027-07-05 Common Stock 105 504336 D All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 14,472 shares). Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.25 to $14.52 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. /s/ Ankit Mahadevia 2020-10-15